Despite the Hawaiian print shirt, Steven Holtzman said retirement has not suited him well — which is why the biotech vet will announce Wednesday that he is taking the helm of Cambridge, Mass., hearing loss startup Decibel Therapeutics.
Decibel’s new CEO is a recent Biogen alum, who also founded Infinity Pharmaceuticals and led the business development team at Millennium Pharmaceuticals.
Armed with a boatload of cash — Decibel raised $52 million in October from Third Rock and GlaxoSmithKline’s venture arm — Holtzman plans to lead the company’s efforts to delve into the molecular pathophysiology of hearing loss and develop new drugs.
About the Author Reprints
